awgldk
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Table
SPARQL
Graphs
1
1
Services
1
1
Assets
0
0
Insights
Schema
BETA
Class frequency
Class hierarchy
Q27853079-33D1C97A-E3D5-42A2-B3B1-496D4B597728
Q27853079-33D1C97A-E3D5-42A2-B3B1-496D4B597728
BestRank
Statement
http://www.wikidata.org/entity/statement/Q27853079-33D1C97A-E3D5-42A2-B3B1-496D4B597728
A phase II study of the efficacy and safety of the combination therapy of the MEK inhibitor refametinib (BAY 86-9766) plus sorafenib for Asian patients with unresectable hepatocellular carcinoma.
P478
Q27853079-33D1C97A-E3D5-42A2-B3B1-496D4B597728
BestRank
Statement
http://www.wikidata.org/entity/statement/Q27853079-33D1C97A-E3D5-42A2-B3B1-496D4B597728
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
9551aef3e2a1c5e3ea40557cbbfd396b8431d159
P478
20
http://www.w3.org/2001/XMLSchema#string